ClinicalTrials.gg
Active, not recruitingNCT05649748Updated Oct 20, 2026

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

A Phase 2/3 interventional study of Treprostinil Palmitil and Placebo in Pulmonary Arterial Hypertension, sponsored by Insmed Incorporated. Active, not recruiting at 45 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Insmed Incorporated · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
91
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 312 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Enrollment
73rd of 253
91 · median 40
Started
2023
with 15 others
Phase 2/3
5 of 312
none open now
Primary completion
2026-12
later than 15 of 55 live
Registered
271st of 312
by date

Among the 312 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 73rd largest by enrollment of the 253 interventional ones that give a count, is one of 16 that started in 2023, is one of 5 in phase 2/3, reaches primary completion later than 15 of the 55 other live ones, and was the 271st registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

38 of the 312 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Treprostinil Palmitil
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants who completed end of treatment study visit in Study INS1009-201, INS1009-202, or any other lead-in PAH TPIP study. Participants for whom the OLE study was not available at the time of their completion of the lead-in study are eligible for enrolment within one year of their lead-in end of treatment visit.
  • Complete baseline screening assessments to confirm eligibility to participate if more than 30 days have elapsed since the end of the study visit in Study INS1009-201, INS1009-202, or any other lead-in PAH TPIP study.

Exclusion criteria

Exclusion Criteria:

  • Initiation of parenteral administration of prostacyclin analogues (eg, TRE, epoprostenol) since the completion of studies INS1009-201, INS1009-202 or other TPIP studies. Initiation of inhaled prostacyclin analogues (eg, TRE [Tyvaso] or iloprost) and oral prostacyclin analogues (eg, TRE [Orenitram]) or receptor agonists (eg, selexipag) are permitted if stopped 24 hours prior to the start of study drug administration.
  • Any new ventricular or supraventricular tachyarrhythmia except for paroxysmal atrial fibrillation and any new symptomatic bradycardia.
  • New-onset of heart disease including (LVEF) ≤40% or valvular, constrictive, or symptomatic atherosclerotic heart disease (eg, stable angina, myocardial infarction, etc).
  • New evidence of thromboembolic disease as assessed by ventilation/perfusion (VQ) scan, pulmonary angiography, or pulmonary computed tomography (CT) scan.
  • Active and current symptomatic coronavirus disease 2019 (COVID-19) or previous severe disease and/or hospitalization due to COVID-19.
  • Interval organ transplantation.
  • New active liver disease or hepatic dysfunction.
  • Interval with exception of completely treated in situ carcinoma of the cervix and completely treated non- squamous or basal cell carcinoma of the skin.
  • Use of any drug/device or participation in any investigational study within 30 days prior to screening, not including TPIP of the lead-in study.
  • Current use of cigarettes (as defined by Centers for Disease Control and Prevention [CDC]) or e-cigarettes: An adult who has smoked at least 100 cigarettes in his or her lifetime, who smokes either every day or some days.
  • Participants who currently inhale marijuana (recreational or medical).

Note: Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Treprostinil Palmitil Inhalation Powder (TPIP)

    Participants who are not transitioning immediately from other TPIP studies:INS1009-201(NCT04791514), INS1009-202(NCT05147805) and other lead-in studies, will be given TPIP, once daily (QD), starting with 80 micrograms (μg), up-titrated to highest tolerated dose between 80 μg and 640 μg during 3-week titration period that maybe increased upto maximum dose of 1280 μg QD post initial titration, per investigator's assessment. Overall treatment period=24 months. Participants transitioning immediately from randomized blinded lead-in TPIP study and who previously received: 1. TPIP- will be given placebo QD(80 μg upto achieved TPIP dose from previous study)along with achieved TPIP dose from previous study in blinded manner during 3-week titration period. 2. Placebo- will be given TPIP QD (80 μg up to achieved placebo dose from previous study)along with achieved placebo dose from previous study in blinded manner during 3-week titration period.Overall treatment period=24 months.

    Drug: Treprostinil Palmitil · Drug: Placebo

Interventions

  • Administered by oral inhalation, using a Plastiape capsule-based dry powder inhaler.

    Also known as: INS1009

  • DrugPlacebo

    Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience at Least one Treatment Emergent Adverse Event (TEAE) and TEAEs by Severity

    Time frame: From screening up to last follow up visit (Up to approximately 26 months)

Secondary outcomes

  1. Absolute Change From Pre-Open Label Extension (OLE) Baseline in 6-Minute Walk Distance (6MWD)

    Time frame: Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24

  2. Relative Change From Pre-OLE Baseline in 6MWD

    Time frame: Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24

  3. Change From Pre-OLE Baseline in the Concentration of N-Terminal Fragment B-Type Natriuretic Peptide (NT-proBNP) in Blood

    Time frame: Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24

  4. Change From Pre-OLE Baseline in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 Score

    Time frame: Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24

  5. Change From Pre-OLE Baseline in New York Heart Association/ World Health Organization (NYHA/WHO) Functional Capacity Class

    Time frame: Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24

  6. Annualized Clinical Worsening Event Rate

    Annualized clinical worsening event rate is defined as the total number of clinical worsening events that occurred during the treatment period divided by the total number of participant-years during the treatment period. Clinical worsening events are one of the following: All-cause death, or onset of TEAE with a fatal outcome occurring ≤ 14 days after study drug discontinuation; Hospitalization for right heart failure (for \> 48 hours), heart-lung or lung transplant, or atrial septostomy; Addition (or increase in dose) of specified PAH-specific medications; Combined occurrence of events including ≥20% decrease in 6MWD, worsening WHO/NYHA functional capacity class, and appearance of or worsening of signs/symptoms of right heart failure from baseline.

    Time frame: OLE Baseline (Day 1) up to Month 24 or early discontinuation

  7. Plasma Concentration Levels of Treprostinil Palmitil (TP) and Treprostinil (TRE)

    Time frame: OLE Baseline (Day 1), Months 6, 12, 18, and 24

07

Study locations

45 sites
  • USA005
    Jacksonville, Florida 32224, United States
  • USA011
    Tampa, Florida 33606, United States
  • USA006
    Chicago, Illinois 60611, United States
  • USA001
    Chicago, Illinois 60612, United States
  • USA102
    New York, New York 10021, United States
  • USA016
    Dallas, Texas 75246, United States
  • ARG009
    Quilmes, Buenos Aires B1878GEG, Argentina
  • ARG006
    Rosario, Santa Fe Province S2013KDS, Argentina
  • ARG007
    San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
  • ARG004
    Córdoba, X5000DCE, Argentina
  • ARG001
    Córdoba, X5000FPQ, Argentina
  • AUT002
    Linz, Upper Austria 4020, Austria
  • AUT001
    Vienna, 1090, Austria
  • BEL003
    Brussels, 1070, Belgium
  • BRA004
    Belo Horizonte, Minas Gerais 30430-142, Brazil
  • BRA006
    Porto Alegre, Rio Grande do Sul 90035-003, Brazil
  • BRA002
    Blumenau, Santa Catarina 89030-101, Brazil
  • DNK001
    Aarhus, Central Jutland 8200, Denmark
  • GER005
    Heidelberg, Baden-Wurttemberg 69126, Germany
  • GER003
    München, Bavaria 80639, Germany
  • GER002
    Lübeck, Schleswig-Holstein 23562, Germany
  • ITA002
    Pavia, Lombardy 27100, Italy
  • ITA005
    Monza, 20900, Italy
  • ITA001
    Palermo, 90127, Italy
  • ITA004
    Roma, 00161, Italy
  • JPN005
    Sapporo, Hokkaido 060-8543, Japan
  • JPN004
    Sapporo, Hokkaido 060-8648, Japan
  • JPN007
    Kurume-shi, Hukuoka 830-0011, Japan
  • JPN006
    Tsukuba, Ibaraki 305-9576, Japan
  • JPN002
    Okayama, Okayama-ken 701-1192, Japan
  • JPN003
    Suita-Shi, Osaka 564-8565, Japan
  • MYS005
    Alor Star, Kedah 5460, Malaysia
  • MYS002
    Kuantan, Pahang 25200, Malaysia
  • MYS004
    Sungai Buloh, Selangor 47000, Malaysia
  • MEX005
    Lomas de Guevara, Jalisco 44657, Mexico
  • MEX001
    Monterrey, Nuevo León 64718, Mexico
  • MEX003
    Mexico City, 14080, Mexico
  • MEX004
    San Luis Potosí City, 78250, Mexico
  • PHL001
    Quezon City, National Capital Region 1100, Philippines
  • PHL002
    Makati City, 1229, Philippines
  • SRB001
    Belgrade, 11000, Serbia
  • SRB003
    Belgrade, 11000, Serbia
  • ESP001
    Santander, 39008, Spain
  • ESP003
    Seville, 41009, Spain
  • GBR001
    Bath, Avon BA1 3NG, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2022
First posted
Dec 14, 2022
StartActual
Mar 7, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05649748
Responsible party
Sponsor
First posted
Dec 14, 2022
Start date
Mar 7, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 20, 2026

Study contacts

Study Director
study director · Insmed Incorporated

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil hexadecyl ester

Start the discussion